A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1878-7479
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice ; day:8 ; month:8 ; year:2022 ; pages:1-15
Neurotherapeutics ; (8.8.2022), 1-15

Creator
Rofo, Fadi
Meier, Silvio R.
Metzendorf, Nicole G.
Morrison, Jamie I.
Petrovic, Alex
Syvänen, Stina
Sehlin, Dag
Hultqvist, Greta
Contributor
SpringerLink (Online service)

DOI
10.1007/s13311-022-01283-y
URN
urn:nbn:de:101:1-2022102422420837385518
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Rofo, Fadi
  • Meier, Silvio R.
  • Metzendorf, Nicole G.
  • Morrison, Jamie I.
  • Petrovic, Alex
  • Syvänen, Stina
  • Sehlin, Dag
  • Hultqvist, Greta
  • SpringerLink (Online service)

Other Objects (12)

Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology

Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease

Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease

Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease

Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease

Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice

Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Related objects